rss
Br J Ophthalmol 2003;87:1509-1514 doi:10.1136/bjo.87.12.1509
  • Laboratory science - Extended reports

Corneal stromal changes following reconstruction by ex vivo expanded limbal epithelial cells in rabbits with total limbal stem cell deficiency

  1. E M Espana1,
  2. S-E Ti2,
  3. M Grueterich1,
  4. A Touhami1,
  5. S C G Tseng1
  1. 1TissueTech, Inc. and Ocular Surface Center, Miami, FL, USA
  2. 2Singapore National Eye Centre, Singapore
  1. Correspondence to: Scheffer C G Tseng MD, PhD, Ocular Surface Center, 7000 SW 97 Avenue, Suite 213, Miami, FL 33173, USA; stsengocularsurface.com
  • Accepted 3 July 2003

Abstract

Aim: To study corneal stromal changes and the presence of myofibroblasts after transplantation of ex vivo expanded limbal epithelium.

Methods: A state of limbal deficiency was induced in 16 rabbits. After transplantation with autologous ex vivo expanded limbal epithelium on amniotic membrane (AM), their clinical outcomes were classified as success, partial success or failure according to surface smoothness, stromal clarity, and vascularisation. Clinical outcomes were correlated with phenotypic outcomes of corneal, conjunctival, or mixed epithelium, defined by expression of K3 keratin or MUC5AC. Immunostaining was performed with antibodies against collagen IV, fibronectin, and α-smooth muscle actin (α-SMA) to assess stromal wound remodelling.

Results: Rabbits were sacrificed after a mean follow up of 10 (SD 3.3) months. Collagen IV, expressed in the basement membrane of all three groups, was found in the stroma of the partial success, but not in that of the success or the failure. Fibronectin was absent in the success and the failure, but expressed in the stroma of the partial success. α-SMA was expressed in superficial stroma of the partial success, but suppressed in areas with AM remnants.

Conclusion: Restoration of a clear and transparent cornea is associated with a normal corneal epithelium and complete wound remodelling. In contrast, wound healing remains active and incomplete in conjunctivalised corneas, which remain opaque with myofibroblasts.

Footnotes

  • Proprietary interest: SCGT and his family are more than 5% shareholders of TissueTech, Inc, which owns US Patent Nos 6,152,142 and 6,326,019 on the method of preparation and clinical uses of human amniotic membrane, distributed by Bio-Tissue, Inc.

  • Presented in part at the annual meeting of ARVO in Ft Lauderdale, FL, USA, in May 2003.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.